We
performed sensitivity analyses using alternative assumptions about prior immunity, contact
patterns between age groups, the proportion of infections that are symptomatic, cost per
unit vaccine, and vaccine effectiveness. Vaccination of children with LAIV was found to be
highly cost-effective, with incremental cost-effectiveness ratios between about 2,000 and
5,000 international dollars per disability-adjusted life year averted, and was consistently preferred
to TIV-based policies. These findings were robust to extensive sensitivity analyses.
Weperformed sensitivity analyses using alternative assumptions about prior immunity, contactpatterns between age groups, the proportion of infections that are symptomatic, cost perunit vaccine, and vaccine effectiveness. Vaccination of children with LAIV was found to behighly cost-effective, with incremental cost-effectiveness ratios between about 2,000 and5,000 international dollars per disability-adjusted life year averted, and was consistently preferredto TIV-based policies. These findings were robust to extensive sensitivity analyses.
การแปล กรุณารอสักครู่..